Micro Interventional Devices’ Permaseal Moves Closer To Regulatory Approval With Early CE Trial Results
Executive Summary
Preliminary 30-day results from the Secure Transapical Access and Closure Study (STASIS) suggest Micro Interventional Devices’ Permaseal device, a transapical access and closure device for structural heart repair, provides safe and effective hemostasis and wound closure after transapical transcatheter aortic valve replacement. The company estimates the worldwide market potential for the device is more than $3 billion annually.
You may also be interested in...
Micro Interventional Devices: Creating A Tool Box For Structural Heart Disease
Micro Interventional Devices was founded around opportunities in addressing the procedural challenges that limit patient access to transcatheter heart valves. The company’s initial focus is on developing a transcatheter valve for the replacement of the mitral valve, and an easy and effective transapical access and closure method for transcatheter mitral and aortic valve procedures. The company’s mission, though, is to broadly focus on advancing structural heart disease treatments, and MID’s first-generation technology has potential application to several areas of structural heart disease, including PFO/atrial septal defect closure, left atrial appendage closure and cardiac ablations.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.